Parexel and Palantir to accelerate clinical data delivery and power clinical outcomes for patients

Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform

Evotech and Variant Bio partner to develop fibrosis treatment

Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program

FDA Granted ODD to Utidelone Injectable from Biostar Pharma for treatment of breast cancer brain metastasis

Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux

Celanese and Secarna Pharmaceuticals collaborate for RNA research for antisense therapies

Bayer and Aignostics to collaborate on next generation precision oncology

Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development

Bristol Myers Squibb inaugurates new US$100 million facility in Hyderabad

The facility will accommodate over 1,500 employees

Roche collaborates with PathAI to expand digital pathology capabilities for companion diagnostics

PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.

Glenmark, Ichnos Sciences form ‘Ichnos Glenmark Innovation’ for new drug discovery in cancer treatment

This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors

EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome

GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year